These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25690599)

  • 1. Evidence gathered from randomized clinical trials and observational studies on the equivalence of emtricitabine and Lamivudine.
    Rokx C; Rijnders BJ
    Clin Infect Dis; 2015 Jun; 60(11):1732-3. PubMed ID: 25690599
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial commentary: Comparative efficacy of lamivudine and emtricitabine: comparing the results of randomized trials and cohorts.
    Ford N; Hill A; Vitoria M; Mills EJ
    Clin Infect Dis; 2015 Jan; 60(1):154-6. PubMed ID: 25273083
    [No Abstract]   [Full Text] [Related]  

  • 3. Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort.
    Rokx C; Fibriani A; van de Vijver DA; Verbon A; Schutten M; Gras L; Rijnders BJ;
    Clin Infect Dis; 2015 Jan; 60(1):143-53. PubMed ID: 25273080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.
    Rokx C; Gras L; van de Vijver D; Verbon A; Rijnders B;
    HIV Med; 2016 Sep; 17(8):571-80. PubMed ID: 26842457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis.
    Dolling DI; Dunn DT; Geretti AM; Sabin CA;
    Clin Infect Dis; 2013 Jan; 56(1):162-3. PubMed ID: 23074305
    [No Abstract]   [Full Text] [Related]  

  • 6. First International Workshop on HIV-1 Persistence During Therapy.
    Pomerantz R; Lafeuillade A;
    HIV Clin Trials; 2004; 5(1):40-9. PubMed ID: 15002086
    [No Abstract]   [Full Text] [Related]  

  • 7. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
    Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
    AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
    Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
    J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. cART reverses hyposplenism in HIV-1 infection.
    Bauer MP; Marijt EW; Kroon FP
    J Acquir Immune Defic Syndr; 2014 Feb; 65(2):e88-90. PubMed ID: 24442232
    [No Abstract]   [Full Text] [Related]  

  • 10. An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study.
    Galli L; Poli A; Muccini C; Galizzi N; Danise A; Spagnuolo V; Gianotti N; Carini E; Lazzarin A; Castagna A
    Infect Dis (Lond); 2018 Mar; 50(3):220-222. PubMed ID: 28891371
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of long-term antiretroviral therapy interruption and resumption on viral reservoir in HIV-1 infected patients.
    Montserrat M; Plana M; Guardo AC; Andrés C; Climent N; Gallart T; Leal L; Gatell JM; Sánchez-Palomino S; García F
    AIDS; 2017 Aug; 31(13):1895-1897. PubMed ID: 28590333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
    Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
    AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid".
    Calcagno A; D'Avolio A; Di Perri G; Bonora S
    J Acquir Immune Defic Syndr; 2013 Apr; 62(4):e118-9. PubMed ID: 24135736
    [No Abstract]   [Full Text] [Related]  

  • 14. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.
    Chéret A; Nembot G; Mélard A; Lascoux C; Slama L; Miailhes P; Yeni P; Abel S; Avettand-Fenoel V; Venet A; Chaix ML; Molina JM; Katlama C; Goujard C; Tamalet C; Raffi F; Lafeuillade A; Reynes J; Ravaux I; Hoën B; Delfraissy JF; Meyer L; Rouzioux C;
    Lancet Infect Dis; 2015 Apr; 15(4):387-96. PubMed ID: 25701561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to Calcagno comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid".
    Cusini A; Ledergerber B; Widmer N; Günthard HF
    J Acquir Immune Defic Syndr; 2013 Oct; 64(2):e14-5. PubMed ID: 24047974
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa.
    Ciaffi L; Koulla-Shiro S; Sawadogo A; le Moing V; Eymard-Duvernay S; Izard S; Kouanfack C; Ngom Gueye NF; Fobang AA; Reynes J; Calmy A; Delaporte E;
    AIDS; 2015 Jul; 29(12):1473-81. PubMed ID: 26244387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A run-in period is needed in randomized controlled trials of directly observed antiretroviral therapy for HIV infection.
    Xia Q; Ning Z; Torian LV
    J Acquir Immune Defic Syndr; 2015 Feb; 68(2):e20-3. PubMed ID: 25590275
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe.
    Swartz JE; Vandekerckhove L; Ammerlaan H; de Vries AC; Begovac J; Bierman WF; Boucher CA; van der Ende ME; Grossman Z; Kaiser R; Levy I; Mudrikova T; Paredes R; Perez-Bercoff D; Pronk M; Richter C; Schmit JC; Vercauteren J; Zazzi M; Židovec Lepej S; De Luca A; Wensing AM;
    J Antimicrob Chemother; 2015; 70(6):1850-7. PubMed ID: 25740950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.
    Maserati R; De Silvestri A; Uglietti A; Colao G; Di Biagio A; Bruzzone B; Di Pietro M; Re MC; Tinelli C; Zazzi M;
    AIDS; 2010 Apr; 24(7):1013-8. PubMed ID: 20124969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent differences in the antiviral effects of highly active antiretroviral therapy in the blood and male genital tract.
    Pasquier CJ; Moinard N; Sauné K; Souyris C; Lavit M; Daudin M; Izopet J; Bujan L
    AIDS; 2008 Sep; 22(14):1894-6. PubMed ID: 18753873
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.